Bank Julius Baer & Co. Ltd, Zurich Fate Therapeutics Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 24, 2023	BUY	$4.76 - $6.59 $1,332 - $1,845	280 New	280 $1,000
Q4 2022 Jan 24, 2023	SELL	$9.86 - $23.83 $89,785 - $216,995	-9,106 Reduced 97.02%	280 $3,000
Q3 2022 Nov 04, 2022	SELL	$21.04 - $36.06 $78,731 - $134,936	-3,742 Reduced 28.5%	9,386 $210,000
Q2 2022 Jul 22, 2022	SELL	$17.78 - $42.39 $107,071 - $255,272	-6,022 Reduced 31.45%	13,128 $325,000
Q1 2022 May 09, 2022	BUY	$29.67 - $60.28 $12,965 - $26,342	437 Added 2.34%	19,150 $742,000
Q4 2021 Feb 15, 2022	BUY	$47.84 - $64.34 $895,229 - $1.2 Million	18,713 New	18,713 $1.1 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.